HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial

Y. Bang, Yubin Kang(Duke University), Akira Sawaki(Aichi Cancer Center), HC Chung, Jing Xu(Sun Yat-sen University), Lin Shen, Suresh H. Advani(Jaslok Hospital), О. Н. Липатов, V. P. Gangadharan, S. R. Park

Journal of Clinical Oncology

May 20, 2008

10.1200/jco.2008.26.15_suppl.4526

Cited by 23

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

|The Lancet Oncology|2013|838

Natural products from true mangrove flora: source, chemistry and bioactivities

|Natural Product Reports|2008|294

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

|Journal of the National Comprehensive Cancer Network|2018|203

Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)

|Journal of Clinical Oncology|2007|158